Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Provided By PR Newswire

Last update: Nov 14, 2024

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03